[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 1785 Introduced in Senate (IS)]
<DOC>
118th CONGRESS
1st Session
S. 1785
To establish programs to address addiction and overdoses caused by
illicit fentanyl and other opioids, and for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
May 31 (legislative day, May 30), 2023
Mr. Markey (for himself, Ms. Warren, Mr. Booker, Mr. Carper, Mr. Wyden,
Mr. Welch, Mr. Menendez, Mr. Merkley, Mr. Blumenthal, and Mr. Heinrich)
introduced the following bill; which was read twice and referred to the
Committee on Health, Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To establish programs to address addiction and overdoses caused by
illicit fentanyl and other opioids, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
(a) Short Title.--This Act may be cited as the ``Stop Fentanyl
Overdoses Act of 2023''.
(b) Table of Contents.--The table of contents for this Act is as
follows:
Sec. 1. Short title; table of contents.
Sec. 2. Definitions.
TITLE I--FENTANYL
Sec. 101. Enhanced fentanyl surveillance.
Sec. 102. Collection of overdose data.
Sec. 103. Public health support for law enforcement.
Sec. 104. Fentanyl detection.
Sec. 105. Grants to improve public health surveillance in forensic
laboratories.
TITLE II--STEMMING THE SUPPLY OF FENTANYL
Sec. 201. Report on countries that produce synthetic drugs.
Sec. 202. GAO report on international mail and cargo screening.
TITLE III--OVERDOSE PREVENTION AND SUBSTANCE USE DISORDER TREATMENT
PROGRAMS
Sec. 301. Opioid treatment education.
Sec. 302. GAO study on naloxone access.
Sec. 303. Increasing access to medication for opioid overdose reversal;
exemption from requirements of the Drug
Supply Chain Security Act.
Sec. 304. Grant program on harms of drug misuse.
Sec. 305. Good Samaritan immunity.
Sec. 306. Report on overdose prevention centers.
Sec. 307. Prisons and substance use disorder treatment.
SEC. 2. DEFINITIONS.
In this Act:
(1) Fentanyl-related substance.--The term ``fentanyl-
related substance'' has the meaning given the term in section
1308.11(h)(30)(i) of title 21, Code of Federal Regulations (or
successor regulations).
(2) Secretary.--The term ``Secretary'' means the Secretary
of Health and Human Services.
TITLE I--FENTANYL
SEC. 101. ENHANCED FENTANYL SURVEILLANCE.
(a) CDC Surveillance Program.--Part J of title III of the Public
Health Service Act is amended by inserting after section 392A (42
U.S.C. 280b-1) the following:
``SEC. 392B. ENHANCED FENTANYL SURVEILLANCE.
``(a) Definition.--In this section, the term `fentanyl-related
substance' has the meaning given the term in section 1308.11(h)(30)(i)
of title 21, Code of Federal Regulations (or successor regulations).
``(b) Data Collection.--The Director of the Centers for Disease
Control and Prevention shall enhance the Overdose Data to Action
program and other drug surveillance programs of the Centers for Disease
Control and Prevention by--
``(1) encouraging States, political subdivisions of States,
and territories to participate in such programs;
``(2) increasing and accelerating the collection of data on
fentanyl, fentanyl-related substances, other synthetic opioids,
and new emerging drugs of abuse (including harmful adulterants
of fentanyl, such as xylazine), including the collection of
related overdose data from medical examiners and drug treatment
admissions and information regarding drug seizures; and
``(3) utilizing available and emerging information on
fentanyl, fentanyl-related substances, other synthetic opioids,
and new emerging drugs of abuse, including information from--
``(A) the High Intensity Drug Trafficking Areas
program under section 707 of the Office of National
Drug Control Policy Reauthorization Act of 1998;
``(B) the National Drug Early Warning System;
``(C) State and local public health authorities;
``(D) Federal, State, and local public health
laboratories; and
``(E) drug seizures by Federal, State, and local
law enforcement agencies, including information from
the National Seizure System and the National Forensic
Laboratory Information System of the Drug Enforcement
Administration.
``(c) Information Sharing.--The Director of the Centers for Disease
Control and Prevention shall publicly disseminate data collected under
this section.
``(d) Authorization of Appropriations.--There are authorized to be
appropriated to carry out this section such sums as are necessary.''.
(b) Law Enforcement Reporting.--Each Federal law enforcement agency
shall report information on all drug seizures by that agency to the
Drug Enforcement Administration for inclusion in the National Seizure
System.
(c) GAO Report.--Not later than 2 years after the date of enactment
of this Act, the Comptroller General of the United States shall--
(1) publish a report analyzing how Federal agencies can
improve their collection, reporting, sharing, and analytic use
of drug seizure data across Federal agencies and with States
and local governments; and
(2) include in such report an analysis of how well
available data on drug seizures can measure progress toward
reducing drug trafficking into and within the United States, as
outlined in strategies such as the National Drug Control
Strategy of the Office of National Drug Control Policy.
SEC. 102. COLLECTION OF OVERDOSE DATA.
(a) In General.--Not later than 2 years after the date of enactment
of this Act, the Secretary shall commence a study on how to most
efficiently track overdoses by type of drug, including fentanyl.
(b) Grant Program.--
(1) In general.--Upon completion of the study under
subsection (a), and taking into consideration the results of
such study, the Secretary shall award grants to States to
facilitate the collection of data with respect to fentanyl-
involved overdoses.
(2) Requirement.--As a condition on receipt of a grant
under this subsection, an applicant shall agree to share the
data collected pursuant to the grant with the Centers for
Disease Control and Prevention.
(3) Preference.--In awarding grants under this subsection,
the Secretary shall give preference to applicants whose grant
proposals demonstrate the greatest need for collecting timely
and accurate data on overdoses.
SEC. 103. PUBLIC HEALTH SUPPORT FOR LAW ENFORCEMENT.
(a) Support for Fentanyl Detection and Handling.--The Secretary, in
consultation with the Attorney General, shall carry out a program to
provide to Federal, State, and local law enforcement agencies training
on accurate information about fentanyl and how to detect and handle
fentanyl.
(b) Evidence-Based.--The program under subsection (a) shall comply
with evidence-based guidelines, including the ``Fentanyl Safety
Recommendations for First Responders'' (or any successor guidelines) of
the Office of National Drug Control Policy.
SEC. 104. FENTANYL DETECTION.
(a) Testing of Contaminants.--The Secretary, acting through the
Assistant Secretary for Mental Health and Substance Use, and in
coordination with the Director of the Centers for Disease Control and
Prevention, shall continue to improve efforts to enhance screening and
identification of contaminants in drugs to prevent overdoses.
(b) Research Into Technologies.--
(1) Definition of chemical screening device.--In this
subsection, the term ``chemical screening device'' means an
infrared spectrophotometer, mass spectrometer, nuclear magnetic
resonance spectrometer, Raman spectrophotometer, ion mobility
spectrometer, or any other device or other technology that is
able to determine the presence of, or identify, one or more
contaminants in drugs.
(2) Research.--The Secretary shall conduct or support
research for the development or improvement of portable and
affordable technologies relating to testing drugs for fentanyl
and fentanyl-related substances, including chemical screening
device methods.
(3) Authorization of appropriations.--There are authorized
to be appropriated to carry out this subsection such sums as
are necessary.
SEC. 105. GRANTS TO IMPROVE PUBLIC HEALTH SURVEILLANCE IN FORENSIC
LABORATORIES.
Title I of the Omnibus Crime Control and Safe Streets Act of 1968
(34 U.S.C. 10101 et seq.) is amended by adding at the end the
following:
``PART PP--CONFRONTING THE USE OF HEROIN, FENTANYL, AND ASSOCIATED
SYNTHETIC DRUGS
``SEC. 3061. AUTHORITY TO MAKE GRANTS TO ADDRESS PUBLIC SAFETY THROUGH
IMPROVED FORENSIC LABORATORY DATA.
``(a) Purpose.--The purpose of this section is to assist States and
units of local government in--
``(1) carrying out programs to improve surveillance of
heroin, fentanyl, fentanyl-related substances, and associated
synthetic drugs to enhance public health;
``(2) improving the ability of States, Tribes, and units of
local government to carry out such programs; and
``(3) carrying out the activities as described in section
101 of the STOP Fentanyl Act of 2023.
``(b) Grant Authorization.--The Attorney General, acting through
the Director of the Bureau of Justice Assistance, may make grants to
States and units of local government to improve surveillance of heroin,
fentanyl, fentanyl-related substances, and associated synthetic drugs
to enhance public health.
``(c) Grant Projects To Improve Surveillance of Seized Heroin,
Fentanyl, and Associated Synthetic Drugs.--Grants made under subsection
(b) shall be used for programs, projects, and other activities to--
``(1) reimburse State, local, or forensic science
laboratories to help address backlogs of untested samples of
heroin, fentanyl, and associated synthetic drugs;
``(2) reimburse State, local, or other forensic science
laboratories for procuring equipment, technology, or other
support systems if the applicant for the grant demonstrates to
the satisfaction of the Attorney General that expenditures for
such purposes would result in improved efficiency of laboratory
testing and help prevent future backlogs;
``(3) reimburse State, local, or other forensic science
laboratories for improved, real time data exchange with the
Centers for Disease Control and Prevention on fentanyl,
fentanyl-related substances, and other associated synthetic
drugs present in the local communities; and
``(4) support State, tribal, and local health department
services deployed to address the use of heroin, fentanyl, and
associated synthetic drugs.
``(d) Limitation.--Not less than 60 percent of the amounts made
available to carry out this section shall be awarded for the purposes
under paragraph (1) or (2) of subsection (c).
``(e) Authorization of Appropriations.--There are authorized to be
appropriated to carry out this section such sums as are necessary.
``(f) Allocation.--
``(1) Population allocation.--Seventy-five percent of the
amount made available to carry out this section in a fiscal
year shall be allocated to each State that meets the
requirements of section 2802 so that each State shall receive
an amount that bears the same ratio to the 75 percent of the
total amount made available to carry out this section for that
fiscal year as the population of the State bears to the
population of all States.
``(2) Discretionary allocation.--Twenty-five percent of the
amount made available to carry out this section in a fiscal
year shall be allocated pursuant to the discretion of the
Attorney General for competitive grants to States or units of
local government with high rates of primary treatment
admissions for polysubstance use, including heroin and other
opioids, for use by State or local law enforcement agencies.
``(3) Minimum requirement.--Notwithstanding paragraphs (1)
and (2), each State shall receive not less than 0.6 percent of
the amount made available to carry out this section in each
fiscal year.
``(4) Certain territories.--
``(A) In general.--For purposes of the allocation
under this section, American Samoa and the Commonwealth
of the Northern Mariana Islands shall be considered as
1 State.
``(B) Allocation amongst certain territories.--For
purposes of subparagraph (A), 67 percent of the amount
allocated shall be allocated to American Samoa and 33
percent shall be allocated to the Commonwealth of the
Northern Mariana Islands.''.
TITLE II--STEMMING THE SUPPLY OF FENTANYL
SEC. 201. REPORT ON COUNTRIES THAT PRODUCE SYNTHETIC DRUGS.
Not later than 1 year after the date of enactment of this Act, the
Secretary of State shall submit to the Committee on the Judiciary and
the Committee on Foreign Relations of the Senate and the Committee on
Energy and Commerce of the House of Representatives a report--
(1) identifying the countries the Secretary determines are
the principal producers of synthetic drugs trafficked into the
United States;
(2) assessing how and why those countries are producing
such drugs; and
(3) describing measures the Secretary plans to take to
reduce the flow of such drugs into the United States.
SEC. 202. GAO REPORT ON INTERNATIONAL MAIL AND CARGO SCREENING.
Not later than 1 year after the date of enactment of this Act, the
Comptroller General of the United States shall submit to Congress a
report reviewing the impact of the High Intensity Drug Trafficking
Areas program on illicit fentanyl and fentanyl-related substances
imported through international mail and cargo, including discussion of
the following:
(1) The volume of fentanyl and fentanyl-related substances
being imported into the United States by means of international
mail and cargo.
(2) The potential impact of increased screening for illicit
fentanyl and fentanyl-related substances on--
(A) deterring drug trafficking in the United
States;
(B) interdicting fentanyl and fentanyl-related
substances that were manufactured outside of the United
States and intended, or attempted, to be imported into
the United States;
(C) the number of Federal criminal prosecutions
based on the manufacture, distribution, or possession
of fentanyl or fentanyl-related substances,
disaggregated by demographic data, including sex, race,
and ethnicity, of the offender;
(D) the charges brought in such prosecutions;
(E) the impacts of prosecutions on reducing demand
and availability to users; and
(F) the development of new fentanyl-related
substances.
(3) The need for noninvasive technology in screening for
fentanyl and fentanyl-related substances, taking into account
the findings pursuant to paragraphs (1) and (2).
TITLE III--OVERDOSE PREVENTION AND SUBSTANCE USE DISORDER TREATMENT
PROGRAMS
SEC. 301. OPIOID TREATMENT EDUCATION.
Part D of title V of the Public Health Service Act (42 U.S.C. 290dd
et seq.) is amended by adding at the end the following:
``SEC. 553. OPIOID TREATMENT EDUCATION.
``(a) In General.--The Secretary shall award grants to States and
local governmental entities to provide education to stakeholders,
including health care providers, criminal justice professionals, and
substance use disorder treatment personnel, on the current state of
research on treatment for opioid use disorder, including--
``(1) the use of opioid agonists or partial agonists; and
``(2) the potential benefits of the use of opioid agonists
or partial agonists for affected individuals.
``(b) Report.--Not later than 1 year after the date of enactment of
the STOP Fentanyl Act of 2023, the Secretary shall submit to the
Committee on Health, Education, Labor, and Pensions of the Senate and
the Committee on Energy and Commerce of the House of Representatives a
report that includes the following data on the education programs
funded pursuant to grants under subsection (a):
``(1) The number of people reached by educational materials
funded pursuant to grants under subsection (a).
``(2) The geographic areas where people received such
educational materials.
``(3) The remaining populations and areas targeted for
awareness of such educational materials, including the
characteristics of such populations and areas, such as the type
of stakeholder.
``(4) The outcomes of education provided pursuant to grants
under subsection (a), as determined by the Secretary.
``(c) Authorization of Appropriations.--There are authorized to be
appropriated to carry out this section such sums as are necessary.''.
SEC. 302. GAO STUDY ON NALOXONE ACCESS.
(a) In General.--The Comptroller General of the United States shall
conduct a study on actions that may be taken to ensure appropriate
access and affordability of naloxone for individuals seeking to
purchase naloxone. Such study shall address what is known about--
(1) coverage of naloxone (in any available form), including
whether naloxone can be covered as an over-the-counter drug
under a group health plan or group or individual health
insurance coverage (as such terms are defined in section 2791
of the Public Health Service Act (42 U.S.C. 300gg-91)) or for
individuals entitled to benefits under part A or enrolled under
part B of title XVIII of the Social Security Act (42 U.S.C.
1395 et seq.), or receiving medical assistance under a State
plan under title XIX of such Act (42 U.S.C. 1396 et seq.) or a
waiver of such plan;
(2) the out-of-pocket cost to consumers purchasing
naloxone--
(A) with a prescription, with and without coverage
under any such plan or coverage;
(B) over-the-counter, with and without coverage
under any such plan or coverage; and
(C) via standing order; and
(3) other factors impacting coverage, including barriers in
covering naloxone as an over-the-counter drug, the relative net
costs of naloxone when purchased over-the-counter without
insurance coverage compared to when purchased with a
prescription and covered under a group health plan or health
insurance coverage, and the availability of naloxone purchased
and distributed through public health entities.
(b) Report.--Not later than 2 years after the date of enactment of
this Act, the Comptroller General of the United States shall submit to
Congress a report that contains the findings of the study conducted
under subsection (a).
SEC. 303. INCREASING ACCESS TO MEDICATION FOR OPIOID OVERDOSE REVERSAL;
EXEMPTION FROM REQUIREMENTS OF THE DRUG SUPPLY CHAIN
SECURITY ACT.
(a) Transactions.--Section 581(24)(B) of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 360eee(24)(B)) is amended--
(1) by redesignating clauses (xvii) and (xviii) as clauses
(xviii) and (xix), respectively; and
(2) by inserting after clause (xvi) the following:
``(xvii) the distribution of an opioid
antagonist indicated for emergency treatment of
opioid overdose, such as naloxone, by or to an
overdose prevention, syringe services program,
or other harm reduction service;''.
(b) Wholesale Distribution.--Section 503(e)(4) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 353(e)(4)) is amended--
(1) by redesignating subparagraphs (R) and (S) as
subparagraphs (S) and (T), respectively; and
(2) by inserting after subparagraph (Q) the following:
``(R) the distribution of an opioid antagonist
indicated for emergency treatment of opioid overdose,
such as naloxone, by or to an overdose prevention,
syringe services program, or other harm reduction
service;''.
SEC. 304. GRANT PROGRAM ON HARMS OF DRUG MISUSE.
Part D of title V of the Public Health Service Act (42 U.S.C. 290dd
et seq.) (as amended by section 301) is amended by adding at the end
the following:
``SEC. 554. GRANT PROGRAM ON HARMS OF DRUG MISUSE.
``(a) In General.--The Assistant Secretary, in consultation with
the Director of the Centers for Disease Control and Prevention, shall
award grants to States and political subdivisions of States to support
the delivery of overdose prevention services, including distribution of
opioid reversal agents approved by the Food and Drug Administration,
such as naloxone, fentanyl strips, and other harm reduction services
that address the harms of drug misuse, including by--
``(1) connecting individuals at risk for, or with, a
substance use disorder to overdose education, counseling, and
health education; and
``(2) encouraging such individuals to take steps to reduce
the harms associated with substance misuse.
``(b) Considerations.--In awarding grants under this section, the
Assistant Secretary shall prioritize grants to applicants that are--
``(1) organizations providing culturally competent care in
terms of considerations based on race, language, ethnicity,
gender, sexuality, or disability; or
``(2) proposing to serve areas with--
``(A) a higher proportion of the population who
meet criteria for dependence on, or abuse of, illicit
drugs;
``(B) a higher drug overdose death rate; and
``(C) a greater behavioral health and substance use
disorder workforce need.
``(c) Special Considerations.--A recipient of a grant under this
section shall--
``(1) ensure that not less than 60 percent of the grant
funds are used for harm reduction programs; and
``(2) prioritize the delivery of opioid antagonists to--
``(A) people who use opioids or illicit drugs;
``(B) families of such people;
``(C) first responders, such as law enforcement
personnel and nonemergency services, such as
firefighters and park rangers; and
``(D) community service providers, such as library,
school, and public transportation personnel.
``(d) Use of Grant Awards.--A recipient of a grant under this
section may use grant funds for the following:
``(1) Adapting, maintaining, and expanding essential
services provided by harm reduction service organizations to
address the risks of drug overdose and contraction of
infectious disease.
``(2) Maintaining or hiring staff.
``(3) Supporting program operational costs, including
staff, rent, and vehicle purchase or maintenance.
``(4) Program supplies.
``(5) Support and case management services.
``(e) Authorization of Appropriations.--There are authorized to be
appropriated to carry out this section such sums as are necessary.''.
SEC. 305. GOOD SAMARITAN IMMUNITY.
(a) In General.--Part B of title II of the Public Health Service
Act (42 U.S.C. 238 et seq.) is amended by adding at the end the
following:
``SEC. 249. GOOD SAMARITAN IMMUNITY.
``(a) Limitation on Civil Liability for Individuals Who Administer
Opioid Overdose Reversal Drugs.--
``(1) In general.--Notwithstanding any other provision of
law, except as provided in paragraph (2), no individual shall
be liable in any Federal or State proceeding for harm caused by
the emergency administration of an opioid overdose reversal
drug to an individual who has or reasonably appears to have
suffered an overdose from heroin or another opioid, if the
individual administers the opioid overdose reversal drug in
good faith.
``(2) Exception.--Paragraph (1) shall not apply to an
individual if the harm was caused by the gross negligence or
reckless misconduct of the individual who administers the drug.
``(3) Definition of opioid overdose reversal drug.--In this
subsection, the term `opioid overdose reversal drug' means a
drug approved under section 505 of the Federal Food, Drug, and
Cosmetic Act that is indicated for the partial or complete
reversal of the pharmacological effects of an opioid overdose
in the human body.
``(b) Immunity From Liability.--
``(1) Immunity.--
``(A) In general.--An individual described in
subparagraph (B) shall not be cited, arrested,
prosecuted, criminally liable, or subject to any
sanction for a violation of a condition of supervised
release under section 404 of the Controlled Substances
Act for the possession or use of a controlled
substance, or under any other provision of Federal law
regulating the misuse of prescription drugs, as a
result of seeking medical assistance as described in
clause (i), (ii), or (iii) of subparagraph (B).
``(B) Individual described.--An individual referred
to in subparagraph (A) is an individual who, in good
faith and in a timely manner--
``(i) seeks medical assistance for another
individual who is experiencing a drug overdose;
``(ii) seeks medical assistance for himself
or herself for a drug overdose; or
``(iii) is the subject of a request for
medical assistance for another individual who
is experiencing a drug overdose.
``(2) Preemption.--This subsection preempts the laws of a
State or any political subdivision of a State to the extent
that such laws are inconsistent with this subsection, unless
such laws provide greater protection from liability.
``(3) Definitions.--In this section:
``(A) Controlled substance.--The term `controlled
substance' has the meaning given the term in section
102 of the Controlled Substances Act.
``(B) Drug overdose.--The term `drug overdose'
means an acute condition resulting from or believed to
be resulting from the use of a controlled substance,
which an individual, who is not a health care
professional, would reasonably believe requires medical
assistance.
``(C) Prescription drug.--The term `prescription
drug' means a drug subject to section 503(b)(1) of the
Federal Food, Drug, and Cosmetic Act.
``(D) Seeks medical assistance; seeking medical
assistance.--The terms `seeks medical assistance' and
`seeking such medical assistance' include--
``(i) reporting a drug or alcohol overdose
or other medical emergency to a law enforcement
authority, the 9-1-1 system, a poison control
center, or a medical provider;
``(ii) assisting another individual who is
making a report described in clause (i); or
``(iii) providing care by administering a
drug to someone who is experiencing a drug or
alcohol overdose or other medical emergency
while awaiting the arrival of medical
assistance.''.
(b) Public Awareness Campaign.--The Secretary, in coordination with
the Administrator of the Drug Enforcement Administration, shall carry
out a campaign to increase public awareness of the limitations on civil
and criminal liability established by section 249 of the Public Health
Service Act (as added by subsection (a)).
SEC. 306. REPORT ON OVERDOSE PREVENTION CENTERS.
The Secretary shall enter into an agreement with the National
Academies of Sciences, Engineering, and Medicine under which the
National Academies shall--
(1) not later than 2 years after the date of the agreement,
submit to Congress a report on overdose prevention centers; and
(2) include in the report required under paragraph (1)--
(A) identification of barriers to operating
overdose prevention centers;
(B) a compilation of the data available to measure
effectiveness of overdose prevention centers on
preventing and reducing regional rates of overdose
deaths, and practices utilized at overdose prevention
centers to improve access to medication for opioid use
disorder and recovery services;
(C) identification of best practices at overdose
prevention centers to promote individual and public
health, provide resources to individuals and families,
improve access to substance use disorder and behavioral
health services, and reduce stigma;
(D) recommendations for developing integrated care
settings inclusive of overdose prevention sites and
incorporating overdose prevention sites into referral
networks; and
(E) recommended approaches to overdose prevention
services that may serve as effective strategies for
recovery for people using fentanyl, fentanyl-related
substances, other synthetic opioids, and new emerging
drugs of abuse (including harmful adulterants of
fentanyl, such as xylazine).
SEC. 307. PRISONS AND SUBSTANCE USE DISORDER TREATMENT.
(a) Prisons and Medication-Assisted Treatment.--
(1) In general.--The Director of the Bureau of Prisons, in
collaboration with the Director of the Office of National Drug
Control Policy, shall establish a program to offer--
(A) all drugs that are approved by the Food and
Drug Administration for treatment of a substance use
disorder;
(B) counseling and other psychosocial treatments
for the treatment of substance use disorder; and
(C) evidence-based withdrawal management services
to individuals in the custody of the Bureau of Prisons
to provide a comprehensive treatment approach substance
use disorders.
(2) Authorization of appropriations.--There are authorized
to be appropriated to carry out this subsection such sums as
are necessary.
(b) Residential Substance Abuse Treatment for State Prisoners.--
Section 1904(d) of title I of the Omnibus Crime Control and Safe
Streets Act of 1968 (34 U.S.C. 10424(d)) is amended--
(1) by striking ``means'' and inserting the following:
``(1) means'';
(2) by striking the period at the end and inserting ``;
and''; and
(3) by adding at the end the following:
``(2) includes any such course of comprehensive individual
and group substance abuse treatment services using medication-
assisted treatment for opioid use disorder (including the use
of any drug approved or licensed by the Food and Drug
Administration for such treatment).''.
<all>